AbbVie Inc ABBV is trading higher Friday after the company announced better-than-expected third-quarter financial results and raised guidance above estimates.
AbbVie reported quarterly adjusted earnings of $3.33 per share, which beat the estimate of $3.22 per share. The company reported quarterly revenue of $14.34 billion, which beat the estimate of $14.32 billion.
AbbVie raised full-year 2021 adjusted earnings guidance from a range of $12.52 to $12.62 per share to a range of $12.63 to $12.67 per share versus the estimate of $12.59 per share.
AbbVie also raised its quarterly dividend from $1.30 per share to $1.41 per share.
"Based upon our strong momentum, we are increasing our full-year 2021 EPS guidance. We remain highly confident in AbbVie's long-term outlook and are once again raising our dividend, which has grown over 250 percent since inception," "said Richard Gonzalez, chairman and CEO of AbbVie.
AbbVie is a drug company with strong exposure to immunology and oncology.
ABBV Price Action: AbbVie has traded as high as $121.53 and as low as $79.11 over a 52-week period.
The stock was up 4.09% at $114.17 at time of publication.
Photo: courtesy of AbbVie.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
